STOCK TITAN

Farallon Capital (EXEL) discloses 13.99M-share Exelixis stake at $308M cost

(Moderate)
(Neutral)
Form Type
SCHEDULE 13D/A

Rhea-AI Filing Summary

Farallon Capital Management, L.L.C. and affiliated individuals report beneficial ownership of 13,989,010 shares of Exelixis, Inc. common stock, representing 5.6% of the company’s outstanding shares. The ownership is reported on an amended Schedule 13D (Amendment No. 8).

The stake is held through a group of investment partnerships collectively referred to as the Farallon Funds, for which Farallon Capital Management acts as investment manager. The percentage is calculated using 247,781,692 Exelixis shares outstanding as of July 27, 2026. The approximate net investment cost for the Farallon Funds’ position is $308,124,978. Recent trading activity over the prior 60 days, all described as open-market transactions, is detailed in an exhibit referenced in the filing. The filing also formalizes a joint filing agreement among the reporting entities and individuals.

Positive

  • None.

Negative

  • None.

Filing Explained

The amendment specifies that eight Farallon investment partnerships hold the reported shares directly, while Farallon Capital Management and its listed managing members report shared voting and dispositive power over 13,989,010 shares; the filing therefore documents control rights alongside economic ownership.

Shares beneficially owned 13,989,010 shares Common shares of Exelixis, Inc. reported as beneficially owned by the Reporting Persons
Ownership percentage 5.6% Portion of Exelixis common stock represented by 13,989,010 shares beneficially owned
Shares outstanding reference 247,781,692 shares Exelixis shares outstanding as of July 27, 2026, used to compute ownership percentage
Approximate net investment cost $308,124,978 Net investment cost for Exelixis shares held by the Farallon Funds
beneficially owned financial
"The Shares reported hereby as beneficially owned by the Reporting Persons are held directly"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
investment manager financial
"Farallon Capital Management, L.L.C., a Delaware limited liability company (the "Investment Manager")"
open-market transactions financial
"All of such transactions were open-market transactions."
Open-market transactions are purchases or sales of a company’s securities that take place on public exchanges rather than through private agreements. They matter to investors because these trades change the number of shares available, can move the stock price, and often signal management’s view of the company’s value—like a store restocking or clearing shelves, altering supply and the price shoppers see.
Schedule 13D regulatory
"If the filing person has previously filed a statement on Schedule 13D to report"
A Schedule 13D is a legal document that investors file with regulators when they buy a large enough stake in a company to potentially influence its management or decisions. It provides details about the investor’s intention, ownership stake, and plans, helping other investors understand who is gaining control and what their motives might be.
joint acquisition statements regulatory
"a written agreement relating to the filing of joint acquisition statements as required by Rule 13d-1(k)"

FAQ

How many EXEL shares does Farallon Capital report owning in this Schedule 13D/A?

Farallon Capital Management and affiliated reporting persons disclose beneficial ownership of 13,989,010 Exelixis (EXEL) common shares. These shares are held through various Farallon-managed investment partnerships referred to as the Farallon Funds in the filing.

What percentage of Exelixis (EXEL) does Farallon’s reported stake represent?

The filing states that Farallon’s reported 13,989,010 shares represent 5.6% of Exelixis’ common stock. This percentage is based on 247,781,692 shares outstanding as of July 27, 2026, as reported by Exelixis in a Form 10-Q.

What is the approximate investment cost of Farallon’s EXEL position?

The Amendment reports an approximate net investment cost of $308,124,978 for the Exelixis shares held by the Farallon Funds. This figure reflects the aggregate cost basis for the position, as disclosed by the reporting persons in Item 3.

Who are the reporting persons in Farallon’s Schedule 13D/A on EXEL?

Reporting persons include Farallon Capital Management, L.L.C. as investment manager and multiple Farallon-managed funds, plus several individuals such as Joshua J. Dapice, Philip D. Dreyfuss, and Hannah E. Dunn, described collectively as the Farallon Individual Reporting Persons.

How were recent EXEL trades by Farallon executed according to the filing?

The filing states that all Exelixis share transactions by the Farallon Funds in the prior sixty days were open-market transactions. Specific trade dates, share amounts, and prices are provided in Exhibit 1.C referenced in the Amendment.

What reference share count does the EXEL Schedule 13D/A use for Farallon’s ownership percentage?

The reported 5.6% ownership is calculated using 247,781,692 Exelixis shares outstanding as of July 27, 2026. This outstanding share count comes from Exelixis’ Form 10-Q filed on August 5, 2026, as cited in the Amendment.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





30161Q104

(CUSIP Number)
Hannah E. Dunn
Farallon Capital Management, L.L.C., One Maritime Plaza, Suite 2100
San Francisco, CA, 94111
(415) 421-2132

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
08/14/2026

(Date of Event Which Requires Filing of This Statement)


If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).




schemaVersion:


SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D






SCHEDULE 13D


Farallon Capital Management, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member
Date:08/14/2026
Farallon Capital Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/14/2026
Farallon Capital Institutional Partners, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/14/2026
Farallon Capital Institutional Partners II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/14/2026
Farallon Capital Institutional Partners III, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/14/2026
Four Crossings Institutional Partners V, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager of its General Partner
Date:08/14/2026
Farallon Capital Offshore Investors II, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/14/2026
Farallon Capital (AM) Investors, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member of its General Partner
Date:08/14/2026
Farallon Capital F5 Master I, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager of its General Partner
Date:08/14/2026
Farallon Healthcare Partners Master, L.P.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager of its General Partner
Date:08/14/2026
Farallon Partners, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Managing Member
Date:08/14/2026
Farallon Institutional (GP) V, L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager
Date:08/14/2026
Farallon F5 (GP), L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager
Date:08/14/2026
Farallon Healthcare Partners (GP), L.L.C.
Signature:/s/ Hannah E. Dunn
Name/Title:Manager
Date:08/14/2026
Dapice Joshua J.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Dreyfuss, Philip D.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Dunn Hannah E.
Signature:/s/ Hannah E. Dunn
Name/Title:Hannah E. Dunn
Date:08/14/2026
Gehani, Varun N.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Giauque, Nicolas
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Husen, Avner A.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Kim, David T.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Linn, Michael G.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Luo Patrick (Cheng)
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Roberts, Jr., Thomas G.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Saito Edric C.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Short Daniel S.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Spokes, Andrew J. M.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Warren, John R.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Wehrly, Mark C.
Signature:/s/ Hannah E. Dunn
Name/Title:Attorney-In-Fact
Date:08/14/2026
Comments accompanying signature:
Each of Farallon Partners, L.L.C., Farallon Institutional (GP) V, L.L.C., Farallon F5 (GP), L.L.C, and Farallon Healthcare Partners (GP), L.L.C. has executed this statement in Mill Valley, California, on behalf of itself and each fund for which it is the general partner.